4,850,000
TB incidence in 2022
170,000
drug-resistant TB incidence in 2022
99,000
TB cases in people with HIV in 2022
The Union's work in South-East Asia
Project Axshya
In collaboration with local partners and over 15,000 community volunteers, The Union provided innovative tuberculosis (TB) interventions designed to serve traditionally hard-to-reach and at-risk populations in India.
Integrated HIV Care Programme - Myanmar
Through its Integrated HIV Care (IHC) Programme, The Union Office in Myanmar currently provides services to nearly 34,000 People Living with HIV, more than 33,400 of which are taking antiretroviral treatment.
The Union's Offices
The Union South-East Asia Office was The Union’s first region office, located in India. The Union Office in Myanmar located in Mandalay provides HIV and TB-HIV programmes.
The Union Office in India
C-6, Qutub Institutional Area
110016 New Delhi
India
Phone: (+91) 11 46 054 400
Phone: (+91) 11 46 054 430 / 429
The Union Office in Myanmar
Ma-10/41-42, 64th St, between 101st & 102nd St
Chan Mya Thar Zi
Mandalay
Myanmar
Phone: (+95) 9 409973377, (+95)9 944973377
Members of The Union South-East Asia Region
The Union is divided into seven regions to provide a platform for addressing lung health and related issues from a regional perspective. This structure offers members opportunities to network with colleagues who face the same regional challenges and contributes to The Union's deep understanding of local issues.
The Union South-East Asia Region is made up of organisational and individual members.
UNION NEWS FROM THE South-East ASIA REGION
The rationale for cancer to be made a notifiable disease in India
A Short Communication in a forthcoming issue of PHA highlights the need to make cancer a notifiable disease in India.
A year in review – evaluating the launch of IJTLD OPEN
An Editorial in a forthcoming issue of IJTLD OPEN describes how open access has driven a dramatic increase in visibility.
Loss to follow-up among adults with drug-resistant TB in Papua New Guinea
An article in a forthcoming issue of PHA assesses the reasons for loss-to-follow-up in patients being treated for disease resistant TB.